Mechanistic Investigation of Five Small-Molecule Inhibitors in the Treatment of Pemphigus Vulgaris via RNA-Seq Analysis
RNA-seq (gene expression) · human · 34 samples
- What it is
- RNA-seq (gene expression)Gene activity measured by sequencing. The summary does not mention single-cell work, so this is most likely bulk: one average per sample, the usual starting point for comparing groups.
- Organism
- Homo sapiens (human)
- Samples
- 34 samples: 7 conditions, mostly with about 5 replicates eachGroups are read from the sample names, not from the paper. Check the list below.
- Data you can get
- A processed table (series matrix) and supplementary files from NCBI; the raw sequencing reads from ENA. Which of these hold counts depends on the study, so check the file list.
Read the full summary ↓
Direct links to NCBI and ENA, no account and no request form. Pick by what you want to do: take the small processed table to look, the supplementary files to re-analyse, or the original raw data to start over.
Processed table
The series matrix: one table of values per sample as the submitters processed it. The smallest download, and it opens in Excel or R. Start here to see what the data look like.
Supplementary files
The count tables and other files the authors uploaded. Take only the samples you need, or the whole study as GSE285009_RAW.tar (it can run to tens of gigabytes).
Raw sequencing reads
The original FASTQ files, straight from the sequencer, held at ENA. Large, and you align them yourself, so only choose this if you need to re-process the study from scratch.
What the files usually look like: For RNA-seq the counts are usually a table among the supplementary files (look for 'counts', 'expression', 'FPKM' or 'TPM' in the file name). The series matrix of a sequencing study is sometimes nearly empty.
Also filed as BioProject PRJNA1200802 and SRA study SRP552828. Searching any of these in the dataset finder brings you back here.
Supports a between-group comparison across 34 samples.
How we read this: 7 replicated groups read from 34 sample titles; they account for 34 of them. These groups are guessed from the sample names, not taken from the paper, so check them against the sample list below before relying on them.
- GSM8694983 NC_rep1 NC
- GSM8694984 PC_rep1 PC
- GSM8694985 A66_rep1 A66
- GSM8694986 BIRB796_rep1 BIRB796
- GSM8694987 GW441756_rep1 GW441756
- GSM8694988 Selumetinib_rep1 Selumetinib
- GSM8694989 Vandetanib_rep1 Vandetanib
- GSM8694990 NC_rep2 NC
- GSM8694991 PC_rep2 PC
- GSM8694992 A66_rep2 A66
- GSM8694993 BIRB796_rep2 BIRB796
- GSM8694994 GW441756_rep2 GW441756
- GSM8694995 Selumetinib_rep2 Selumetinib
- GSM8694996 Vandetanib_rep2 Vandetanib
- GSM8694997 NC_rep3 NC
- GSM8694998 PC_rep3 PC
- GSM8694999 A66_rep3 A66
- GSM8695000 BIRB796_rep3 BIRB796
- GSM8695001 GW441756_rep3 GW441756
- GSM8695002 Vandetanib_rep3 Vandetanib
- GSM8695003 NC_rep4 NC
- GSM8695004 PC_rep4 PC
- GSM8695005 A66_rep4 A66
- GSM8695006 BIRB796_rep4 BIRB796
- GSM8695007 GW441756_rep4 GW441756
- GSM8695008 Selumetinib_rep4 Selumetinib
- GSM8695009 Vandetanib_rep4 Vandetanib
- GSM8695010 NC_rep5 NC
- GSM8695011 PC_rep5 PC
- GSM8695012 A66_rep5 A66
- GSM8695013 BIRB796_rep5 BIRB796
- GSM8695014 GW441756_rep5 GW441756
- GSM8695015 Selumetinib_rep5 Selumetinib
- GSM8695016 Vandetanib_rep5 Vandetanib
- GSE222196 Treatment of prostate cancer cell lines with Androgen Receptor and Receptor Tyrosine Kinase inhibitors 246 samples shares inhibitors, treatment
- GSE305224 Covalent pan-TEAD inhibitors block YAP activity and demonstrate brain penetrance in Hippo-dependent cancer models [RNA-seq] 120 samples shares inhibitors, rna-seq
- GSE281517 Lysosomal sequestration of PARP inhibitors drives heterogeneous accumulation in ovarian cancer to increase efficacy [RNA-seq] 72 samples shares inhibitors, rna-seq
- GSE334345 Exploratory investigation of changes in blood transcriptome following mepolizumab treatment for asthma 54 samples shares investigation, treatment
- GSE240581 Small-molecule Inhibition of METTL3 Suppresses Tumor Growth and Promotes Neuroblastoma Differentiation [RNA-Seq Decay] 48 samples shares small-molecule, rna-seq
- GSE302434 Bromodomain Inhibitors to Prevent Development of Resistance to Targeted Kinase Inhibitors in Schwannomas [RNA-seq] 43 samples shares inhibitors, rna-seq
- GSE295647 Catalytic inhibition of KAT6/KAT7 enhances the efficacy and overcomes primary and acquired resistance to Menin inhibitors in acute myeloid leukaemia [human RNA-seq] 36 samples shares inhibitors, rna-seq
- GSE324093 ESR1 mutations shape the clonal dynamics, genetic diversity and cellular states of acquired resistance to CDK4/6 inhibitors [RNA-seq] 32 samples shares inhibitors, rna-seq
Metadata from NCBI GEO, cached and refreshed periodically — the NCBI page above is authoritative. Downloads link straight to NCBI/ENA; nothing is proxied through BioTransfer.